The epidemiology, pathogenesis, transmission, diagnosis, and management of multidrug-resistant, extensively drug-resistant, and incurable tuberculosis
Global tuberculosis incidence has declined marginally over the past decade, and
tuberculosis remains out of control in several parts of the world including Africa and Asia …
tuberculosis remains out of control in several parts of the world including Africa and Asia …
Tuberculosis: progress and advances in development of new drugs, treatment regimens, and host-directed therapies
Tuberculosis remains the world's leading cause of death from an infectious disease,
responsible for an estimated 1 674 000 deaths annually. WHO estimated 600 000 cases of …
responsible for an estimated 1 674 000 deaths annually. WHO estimated 600 000 cases of …
Drug-associated adverse events in the treatment of multidrug-resistant tuberculosis: an individual patient data meta-analysis
Background Treatment of multidrug-resistant tuberculosis requires long-term therapy with a
combination of multiple second-line drugs. These drugs are associated with numerous …
combination of multiple second-line drugs. These drugs are associated with numerous …
Effectiveness and safety of bedaquiline-containing regimens in the treatment of MDR-and XDR-TB: a multicentre study
SE Borisov, K Dheda, M Enwerem… - European …, 2017 - Eur Respiratory Soc
Large studies on bedaquiline used to treat multidrug-resistant (MDR-) and extensively drug-
resistant tuberculosis (XDR-TB) are lacking. This study aimed to evaluate the safety and …
resistant tuberculosis (XDR-TB) are lacking. This study aimed to evaluate the safety and …
Towards tuberculosis elimination: an action framework for low-incidence countries
K Lönnroth, GB Migliori, I Abubakar… - European …, 2015 - Eur Respiratory Soc
This paper describes an action framework for countries with low tuberculosis (TB) incidence
(< 100 TB cases per million population) that are striving for TB elimination. The framework …
(< 100 TB cases per million population) that are striving for TB elimination. The framework …
Advances in the development of new tuberculosis drugs and treatment regimens
Despite the introduction 40 years ago of the inexpensive and effective four-drug (isoniazid,
rifampicin, pyrazinamide and ethambutol) treatment regimen, tuberculosis (TB) continues to …
rifampicin, pyrazinamide and ethambutol) treatment regimen, tuberculosis (TB) continues to …
[PDF][PDF] Technical report on the pharmacokinetics and pharmacodynamics (PK
World Health Organization - 2018 - apps.who.int
With an estimated 1.7 million deaths attributed to it each year, tuberculosis (TB) is the single
leading infectious cause of death in the world. Combined chemotherapy has been the …
leading infectious cause of death in the world. Combined chemotherapy has been the …
Management of patients with multidrug-resistant/extensively drug-resistant tuberculosis in Europe: a TBNET consensus statement
The emergence of multidrug-resistant (MDR) and extensively drug-resistant (XDR)
tuberculosis (TB) substantially challenges TB control, especially in the European Region of …
tuberculosis (TB) substantially challenges TB control, especially in the European Region of …
Tuberculosis—advances in development of new drugs, treatment regimens, host-directed therapies, and biomarkers
Tuberculosis is the leading infectious cause of death worldwide, with 9· 6 million cases and
1· 5 million deaths reported in 2014. WHO estimates 480 000 cases of these were multidrug …
1· 5 million deaths reported in 2014. WHO estimates 480 000 cases of these were multidrug …
Global control of tuberculosis: from extensively drug-resistant to untreatable tuberculosis
Extensively drug-resistant tuberculosis is a burgeoning global health crisis mainly affecting
economically active young adults, and has high mortality irrespective of HIV status. In some …
economically active young adults, and has high mortality irrespective of HIV status. In some …